Krebs Biochemicals Earnings Per Share vs. EBITDA
| KREBSBIO | 104.14 8.79 7.78% |
For Krebs Biochemicals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Krebs Biochemicals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Krebs Biochemicals and utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Krebs Biochemicals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Krebs Biochemicals and over time as well as its relative position and ranking within its peers.
Krebs |
Krebs Biochemicals and EBITDA vs. Earnings Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Krebs Biochemicals's current stock value. Our valuation model uses many indicators to compare Krebs Biochemicals value to that of its competitors to determine the firm's financial worth. Krebs Biochemicals and is currently regarded as number one stock in earnings per share category among its peers. It also is currently regarded as number one stock in ebitda category among its peers . As of now, Krebs Biochemicals' EBITDA is decreasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Krebs Biochemicals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Krebs Biochemicals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Krebs EBITDA vs. Earnings Per Share
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Krebs Biochemicals |
| = | (10.10) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Krebs Biochemicals |
| = | (82.73 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Krebs EBITDA Comparison
Krebs Biochemicals is currently under evaluation in ebitda category among its peers.
Krebs Biochemicals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Krebs Biochemicals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Krebs Biochemicals will eventually generate negative long term returns. The profitability progress is the general direction of Krebs Biochemicals' change in net profit over the period of time. It can combine multiple indicators of Krebs Biochemicals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 114.4 M | 120.2 M | |
| Operating Income | -152 M | -159.6 M | |
| Income Before Tax | -197.3 M | -207.1 M | |
| Total Other Income Expense Net | -45.3 M | -47.6 M | |
| Net Loss | -197.3 M | -207.1 M | |
| Income Tax Expense | 67.5 M | 70.9 M | |
| Net Loss | -197.3 M | -207.1 M | |
| Net Loss | -222.2 M | -233.3 M | |
| Interest Income | 34.2 M | 40.7 M | |
| Net Interest Income | -46.9 M | -49.2 M | |
| Change To Netincome | 58.8 M | 61.8 M |
Krebs Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Krebs Biochemicals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Krebs Biochemicals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Krebs Biochemicals' important profitability drivers and their relationship over time.
Use Krebs Biochemicals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krebs Biochemicals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krebs Biochemicals will appreciate offsetting losses from the drop in the long position's value.Krebs Biochemicals Pair Trading
Krebs Biochemicals and Pair Trading Analysis
The ability to find closely correlated positions to Krebs Biochemicals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krebs Biochemicals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krebs Biochemicals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krebs Biochemicals and to buy it.
The correlation of Krebs Biochemicals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krebs Biochemicals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krebs Biochemicals and moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krebs Biochemicals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Krebs Biochemicals position
In addition to having Krebs Biochemicals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Krebs Stock
To fully project Krebs Biochemicals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Krebs Biochemicals and at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Krebs Biochemicals' income statement, its balance sheet, and the statement of cash flows.